Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome

European Urology

Volumn 69, Issue 2, 2016, Pages 311-323

  Rosa, Gian Marco ^a   Ferrero, Simone ^a   Nitti, Victor W ^b   Wagg, Adrian ^c   Saleem, Tahir ^d   Chapple, Christopher R ^e  

^a UNIVERSITY OF GENOA   (Italy)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular; Overactive bladder; Safety; 3 Adrenoceptor agonist

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; MIRABEGRON; RAFABEGRON; RITOBEGRON; SOLABEGRON; TAMSULOSIN; TOLTERODINE; ACETANILIDE DERIVATIVE; ANILINE DERIVATIVE; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; THIAZOLE DERIVATIVE;

CARDIOVASCULAR EFFECT; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; MEDLINE; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; ELECTROCARDIOGRAPHY; URINARY BLADDER, OVERACTIVE;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANILINE COMPOUNDS; BENZOATES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; THIAZOLES; URINARY BLADDER, OVERACTIVE;

EID: 84952870799     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.09.007     Document Type: Review

References (46)

1. D.E. Irwin, Z.S. Kopp, B. Agatep, I. Milsom, and P. Abrams Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction BJU Int 108 2011 1132 1138
2. I. Milsom, and D.E. Irwin A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC study Eur Urol 6 Suppl 1 2007 4 9
3. W.F. Stewart, J.B. Van Rooyen, G.W. Cundiff, and et al. Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327 336
4. K.E. Andersson, C. Sarawate, K.H. Kahler, E.L. Stanley, and A.S. Kulkarni Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder BJU Int 106 2010 268 274
5. S.A. Macdiarmid Maximizing the treatment of overactive bladder in the elderly Rev Urol 10 2008 6 13
6. K.S. Coyne, C.C. Sexton, D.E. Irwin, Z.S. Kopp, C.J. Kelleher, and I. Milsom The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study BJU Int 101 2008 1388 1395
7. U. Leone Roberti Maggiore, S. Salvatore, F. Alessandri, and et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females Expert Opin Drug Metab Toxicol 8 2012 1387 1408
8. G.M. Rosa, M. Bauckneht, C. Scala, and et al. Cardiovascular effects of antimuscarinic agents in overactive bladder Expert Opin Drug Saf 12 2013 815 827
9. M.C. Michel, and W. Vrydag Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate Br J Pharmacol 147 Suppl 2 2006 S88 S119
10. A. Otsuka, H. Shinbo, R. Matsumoto, Y. Kurita, and S. Ozono Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium Naunyn Schmiedebergs Arch Pharmacol 377 2008 473 481
11. O. Yamaguchi Beta3-adrenoceptors in human detrusor muscle Urology 59 2002 25 29
12. M. Wuest, B. Eichhorn, M.O. Grimm, M.P. Wirth, U. Ravens, and A.J. Kaumann Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man J Pharmacol Exp Ther 328 2009 213 222
13. V.A. Skeberdis, V. Gendviliene, D. Zablockaite, and et al. beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current J Clin Invest 118 2008 3219 3227
14. O.E. Brodde, and M.C. Michel Adrenergic and muscarinic receptors in the human heart Pharmacol Rev 51 1999 651 690
15. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Betmiga. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002388/WC500137308.pdf.
16. A.B. Grudell, M. Camilleri, K.L. Jensen, and et al. Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health Am J Physiol Gastrointest Liver Physiol 294 2008 G1114 G1119
17. L.M. Redman, L. de Jonge, X. Fang, and et al. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study J Clin Endocrinol Metab 92 2007 527 531
18. H. Harada, Y. Hirokawa, K. Suzuki, and et al. Discovery of a novel and potent human and rat beta3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]ac etic acid Chem Pharm Bull (Tokyo) 53 2005 184 198
19. 3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat Naunyn Schmiedebergs Arch Pharmacol 385 2012 845 852
20. 3-adrenoceptor agonist, on bladder function in cynomolgus monkey J Pharmacol Exp Ther 342 2012 163 168
21. 3-adrenoceptor agonist, on mammalian detrusor strips Urology 79 2012 744.e1-7
22. N.M. Wheeldon, D.G. McDevitt, and B.J. Lipworth Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man Br J Clin Pharmacol 37 1994 363 369
23. M.G. Ursino, V. Vasina, E. Raschi, F. Crema, and F. De Ponti The beta3-adrenoceptor as a therapeutic target: current perspectives Pharmacol Res 59 2009 221 234
24. V. Nitti, V. Khullar, P. van Kerrebroeck, and et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies Int J Clin Pract 67 2013 619 632
25. 3-adrenoceptor agonist, in overactive bladder Eur Urol 63 2013 296 305
26. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
27. Advisory committee briefing document. Mirabegron (YM178) for the treatment of overactive bladder, April 5, 2012. US Food and Drug Administration Web site. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM298285.pdf.
28. H.C. Kuo, K.S. Lee, Y. Na, and et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia Neurourol Urodyn 34 2015 685 692
29. C.R. Chapple, V. Dvorak, P. Radziszewski, and et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder Int Urogynecol J 24 2013 1447 1458
30. O. Yamaguchi, E. Marui, H. Kakizaki, and et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder BJU Int 113 2014 951 960
31. C.R. Chapple, G. Amarenco, M.A. Lopez Aramburu, and et al. A proof-of-concept study: Mirabegron, a new therapy for overactive bladder Neurourol Urodyn 32 2013 1116 1122
32. M. Malik, E.M. van Gelderen, J.H. Lee, and et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study Clin Pharmacol Ther 92 2012 696 706
33. Myrbetriq [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; 2012.
34. W. Krauwinkel, J. van Dijk, M. Schaddelee, and et al. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women Clin Ther 34 2012 2144 2160
35. H. Iitsuka, T. Tokuno, Y. Amada, and et al. Pharmacokinetics of mirabegron, a beta3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies Clin Drug Investig 34 2014 27 35
36. M. van Gelderen, R. Tretter, J. Meijer, and et al. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men Int J Clin Pharmacol Ther 52 2014 693 701
37. E.H. Ohlstein, A. von Keitz, and M.C. Michel A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-adrenoceptor agonist solabegron for overactive bladder Eur Urol 62 2012 834 840
38. Food Drug Administration HHS. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability Notice. Fed Regist 70 2005 61134 61135
39. C. Gauthier, B. Rozec, B. Manoury, and J.L. Balligand Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies Curr Heart Fail Rep 8 2011 184 192
40. Background document for meeting of Advisory Committee for Reproductive Health Drugs, April 5, 2012. NDA 202611 Mirabegron Tablets. Astellas Pharma Global Development. US Food and Drug Administration Web site. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM298641.pdf.
41. 3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial Eur Urol 63 2013 283 295
42. V.W. Nitti, S. Auerbach, N. Martin, A. Calhoun, M. Lee, and S. Herschorn Results of a randomized phase III trial of mirabegron in patients with overactive bladder J Urol 189 2013 1388 1395
43. 3-adrenoceptor agonist Clin Drug Investig 33 2013 429 440
44. W. Krauwinkel, J. Dickinson, M. Schaddelee, and et al. The effect of mirabegron, a potent and selective beta3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol Eur J Drug Metab Pharmacokinet 39 2014 43 52
45. Toviaz (fesoterodine fumarate) [package insert] 2012 Pfizer Inc New York, NY
46. X.R. Sanctura (trospium chloride) [package insert] 2012 Allergan Inc Irvine, CA